Home Online Features TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Hand-out
Press Releases
Johnson & Johnson, ECCO  
February 21, 2025

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients

logo salamanca press

Salamanca Press

email salamanca press
Local & Social